CirrhosisRT-ELASTONCT01948687
Real Time Elastography in Liver Fibrosis
An observational study of Cirrhosis and Chronic Liver Disease, run by University of Medicine and Pharmacy Craiova at 2 sites in Romania.
Trial summary
AIM To evaluate the role of real time elastography (ARFI and Hitachi elastography) in noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cirrhosis, Chronic Liver Disease
- How many people
- 500 participants
- Where
- 2 sitesRomania
- Study dates
- Aug 2013to Nov 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The patients included in the study will be healthy voluntaries, patients with chronic hepatitis B or C and patients with liver cirrhosis. ARFI and Hitachi elastography will be performed for each patient and the results will be compared with final diagnosis. The final diagnosis (the stage) will be established based on Transient elastography and or liver biopsy.
Who may be able to join
- age over 18 years old
- Study will include three groups of patients as follows:
- Group I: patients with chronic hepatitis B or C (defined by the presence of serum anti HCV antibody or serum hepatitis B surface antibody)
- Group II (the control group): healthy adult volunteers
- Group III: patients with hepatic cirrhosis type B or C
- There at least one reference method available for patients with chronic hepatitis (Transient elastography/ liver biopsy)
- Hepatic cirrhosis diagnosis is established using clinical and paraclinical features (ultrasonography, superior digestive endoscopy)
- A written informed consent is given to each patient
Who cannot join
- Patients with contraindication for elastography (pregnant women or who are breastfeeding) and patients with pacemakers
- Patients with liver disease of other etiology than viral infection (autoimmune hepatitis, primary biliary hepatitis, primary sclerosing cholangitis, hemochromatosis, alfa 1-antitrypsin deficiency, or Wilson's disease)
- History of alcohol abuse (alcohol intake> 20g/day)
- Patients under treatment with hepatotoxic drugs (methotrexate, amiodarone, corticotherapy , chemotherapy, hormonotherapy)
- Patients with technically unfeasible TE: patients with ascites
Trial locations and contacts
2 sites in 1 country.
Romania2 sites, 2 recruiting
- Recruiting
Researche Center of Gastroenterology and Hepatology
Craiova, Dolj, 200635
Larisa Sandulescu, MD, PhD, 40723968354, larisasandulescu@yahoo.com
Adrian Saftoiu, Md, PhD
- Recruiting
University of Medicine and Pharmacy
Timișoara, Timiș County, 200635
Alina Popescu, MD, PhD, alinamirceapopescu@yahoo.com
Ioan Sporea, MD, PhD
About this study
Official title: The Role of Real Time Elastography in the Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis
AIM To evaluate the role of real time elastography (ARFI and Hitachi elastography) in noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis
Read the detailed description
INTRODUCTION
Establishing liver fibrosis grade in patients with chronic viral hepatitis is very important for the prognostic assessment and in making the decision to initiate antiviral treatment. Although the liver biopsy remains the gold standard, recent studies focused on establishing the role of noninvasive methods in liver fibrosis grading.
Elastography is an imaging method which estimates tissue elasticity. The first elastography method which appeared was Transient Elastography (TE), followed by Real Time Elastography (RT-E) and Acoustic Radiation Force Impulse (ARFI). TE was a method especially developed for noninvasive assessment of liver fibrosis as an alternative to liver biopsy. Unlike these, RT-E and ARFI have multiple applications in diffuse and tumoral pathology.
Transient Elastography (FibroScan) represents a noninvasive method useful in detecting the degree of liver fibrosis. The ultrasound transducer probe is able to generate elastic shear waves that propagate through the liver tissue as well as to measure their speed in the tissue. Wave speed is directly related to tissue stiffness which is expressed in kilopascals [1]. Initially, this method was validated for use and considered for chronic hepatitis management guidelines, then for human immunodeficiency virus/hepatitis C virus (HCV) co-infection and cholestatic liver diseases. FibroScan failures to give reliable results in obese patients were reduced by developing a new XL probe which facilitated an alternative noninvasive method to liver biopsy for liver fibrosis assessment [2].
Acoustic Radiation Force Impulse (ARFI) was proposed as an alternative to FibroScan for the assessment of liver tissue elasticity, using a conventional ultrasound machine. The main advantages of this method are the possibility of producing real-time images and its feasibility in patients with ascites. Preliminary studies show better results for predicting advanced grades of liver fibrosis than for mild to moderate fibrosis where the method is less sensitive [3].
Real Time Elastography (RT-E) estimates relative tissue stiffness based on soft tissue distortion and data are provided as real time color images [4, 5]. This is a real time method that could also be used for patients with ascites. The method is not validated for liver fibrosis assessment as there are few studies published so far. The appearance of the elastography software on the convex probe with high penetration and possibility for elastography to visualize the liver entirely and the development of information elastography measurement information programs open new perspectives in noninvasive assessment of liver pathology by RT-E. There are two recent studies showing good results of the software for quantitative analysis in RT-E equipment.
The aim of this study is to establish the role of elastographic methods (ARFI and RT-E) in liver fibrosis assessment in patients with chronic viral hepatitis. This multicentric prospective trial will be approved by the ethical committee of each centre.
AIM To evaluate the role of real time elastography (ARFI and Hitachi elastography) in noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis.
MATERIAL AND METHODS
- All patients are enrolled consecutively.
- Patient data are collected (name initials, age, sex, Civil Registration Number), liver disease etiology, anthropometric data (body mass index).
- The following blood parameters are included: aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ -glutamyl transpeptidase, γ globulins, platelet count
- The following indices are calculated: AST/ALT; AST-to-platelet ratio index (APRI); AST/upper limit of normal 100/platelet count (104 /mm3 ) , and FibroIndex [1.738 0.064 x platelet count (104 /mm3 ) + 0.005 x AST (U/l) + 0.463 x γ -globulin (g/dl)]
- Transient elastography is performed using FibroScan (FibroScan, Echosens) with the patient lying in the dorsal decubitus position and with his right arm in maximum abduction. The tip of the transducer probe is placed in the median axillary line in the intercostal space corresponding to the right lobe of the liver. The pressure index on the screen indicates that the pressure applied with the probe is compatible with the measurement. Ten measurements per examination are necessary for good accuracy of the stiffness assessment, considering the final result expressed in kilopascals as the mean of the ten measurements. M and XL probes for obese patients are used.
- Hitachi Real Time Ultrasound Elastography is performed using the 5-1 MHz (EUP) convex transducer from Hitachi Preirus equipment (Hitachi Aloka Medical Tokyo, Japan). Dual imaging is set in such a manner as to be visible on the screen in a 2D image as well as in an elastographic image juxtaposed over the 2D image. The examination is underwent through two points: intercostally through the right lobe and epigastrically through left hepatic lobe. The examination is done through post-expiratory apnea without compression on the probe. The interest region (ROI) is set at 4cm², 1 cm under the liver capsule. The aria of interest is chosen so that the 2D image is as clear as possible, the large vessels avoided and the artifacts given by ribs and lungs. For each patient, 10 images are chosen with two entry points (intercostally and epigastrically). For each image the 11 parameters given by the Strain Histogram measurement software are used: mean relative strain value (MEAN); standard deviation of relative strain value (SD); percentage of low strain area (percentage of blue color area - %AREA); complexity of low strain area (calculated as perimeter 2 /area - COMP); skewness (SKEW); kurtosis (KURT); contrast (CONT); entropy (ENT); textural complexity, inverse difference moment (IDM); angular second moment (ASM); Correlation (CORR) indicates the feature value of the texture directivity.
- ARFI- Acoustic Radiation Force Impulse Technology [ACUSON S2000]. Scanning is performed with a right intercostal approach, in the right liver lobe, segment V-VIII, 1-2 cm under the liver capsule, with minimal scanning pressure applied by the operator, while the patients is asks to stop normal breathing for a moment, in order to minimize breathing motion. The operator selects the depth at which the liver elasticity is evaluated by placing a "measuring box" (10 mm long, 5 mm wide) in the desired area. The maximum depth at which ARFI measurements can be performed is 8 cm. A total of 10 valid measurements performe in every patient and a median value in m/s is calculate.
- Liver biopsy samples is takes via a right intercostal space from the right liver lobe with direct sonographic guidance. Liver fibrosis stages is evaluate semiquantitatively according to the METAVIR scoring system on an F0-F4 scale
Statistical analysis
The diagnostic performance of ARFI and RT-E for liver fibrosis will determine in terms of sensitivity, specificity, positive predictive value, negative predictive value, diagnostic accuracy and area under the receiver operating characteristic curve (AUROC).
- Conditions
- Cirrhosis, Chronic Liver Disease
- Keywords
- real time elastography, hepatitis
- Medical subject headings
- Fibrosis, Hepatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1. the control group | healthy adult volunteers | |
| 2. patients with chronic hepatitis | patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen) | |
| 3. liver cirrhosis type B or C | patients with liver cirrhosis type B or C |
What is being measured
The primary outcome is the main question the study is designed to answer.
Real Time Elastography result
Value of real time elastography recordings for the evaluation of liver fibrosis.
Measured: up to 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2013 (estimated)
- Study startAug 2013
- Primary completionMar 2014 (estimated)
- Study completionNov 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CirrhosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Medicine and Pharmacy Craiova
- Sponsor type
- University, hospital or other
- Collaborators
- University of Medicine and Pharmacy "Victor Babes" Timisoara
- Responsible party
- Principal investigator, Dan Gheonea, University of Medicine and Pharmacy Craiova
- Investigators
- Adrian Saftoiu, MD, PhD, Principal investigator, UMF Craiova
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01948687
- Sponsor's protocol ID
- RT-ELASTO
- Acronym
- RT-ELASTO
- Status last verified
- Sep 2013
- First submitted
- 3 Sep 2013
- Last updated
- 24 Sep 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
1. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48: 835-847. 2. V de Lédinghen, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010 Aug; 30 (7): 1043-8. 3. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012 Feb; 19 (2): 212-9. 4. Koizumi Y, Hirooka M, Kisaka Y et al. Liver fibrosis in patients with chronic hepatitis C: noninvasive diagnosis by means of real-time tissue elastography--establishment of the method for measurement. Radiology. 2011; 258: 610-617. 5. Gheonea DI, Săftoiu A, Ciurea T et al. Real-time sono-elastography in the diagnosis of diffuse liver diseases. World J Gastroenterol. 2010; 16: 1720-1726.
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Real Time Elastography in the Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis
- ClinicalTrials.gov ID
- NCT01948687
- Acronym / sponsor ID
- RT-ELASTO / RT-ELASTO
- Conditions
- Cirrhosis, Chronic Liver Disease
- Keywords
- real time elastography, hepatitis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- University of Medicine and Pharmacy CraiovaUniversity, hospital or other
- Collaborators
- University of Medicine and Pharmacy "Victor Babes" Timisoara
- Study start
- Aug 2013
- Primary completion
- Mar 2014 (estimated)
- Study completion
- Nov 2014 (estimated)
- First posted
- 24 Sep 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AIM To evaluate the role of real time elastography (ARFI and Hitachi elastography) in noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis
Detailed description
INTRODUCTION
Establishing liver fibrosis grade in patients with chronic viral hepatitis is very important for the prognostic assessment and in making the decision to initiate antiviral treatment. Although the liver biopsy remains the gold standard, recent studies focused on establishing the role of noninvasive methods in liver fibrosis grading.
Elastography is an imaging method which estimates tissue elasticity. The first elastography method which appeared was Transient Elastography (TE), followed by Real Time Elastography (RT-E) and Acoustic Radiation Force Impulse (ARFI). TE was a method especially developed for noninvasive assessment of liver fibrosis as an alternative to liver biopsy. Unlike these, RT-E and ARFI have multiple applications in diffuse and tumoral pathology.
Transient Elastography (FibroScan) represents a noninvasive method useful in detecting the degree of liver fibrosis. The ultrasound transducer probe is able to generate elastic shear waves that propagate through the liver tissue as well as to measure their speed in the tissue. Wave speed is directly related to tissue stiffness which is expressed in kilopascals [1]. Initially, this method was validated for use and considered for chronic hepatitis management guidelines, then for human immunodeficiency virus/hepatitis C virus (HCV) co-infection and cholestatic liver diseases. FibroScan failures to give reliable results in obese patients were reduced by developing a new XL probe which facilitated an alternative noninvasive method to liver biopsy for liver fibrosis assessment [2].
Acoustic Radiation Force Impulse (ARFI) was proposed as an alternative to FibroScan for the assessment of liver tissue elasticity, using a conventional ultrasound machine. The main advantages of this method are the possibility of producing real-time images and its feasibility in patients with ascites. Preliminary studies show better results for predicting advanced grades of liver fibrosis than for mild to moderate fibrosis where the method is less sensitive [3].
Real Time Elastography (RT-E) estimates relative tissue stiffness based on soft tissue distortion and data are provided as real time color images [4, 5]. This is a real time method that could also be used for patients with ascites. The method is not validated for liver fibrosis assessment as there are few studies published so far. The appearance of the elastography software on the convex probe with high penetration and possibility for elastography to visualize the liver entirely and the development of information elastography measurement information programs open new perspectives in noninvasive assessment of liver pathology by RT-E. There are two recent studies showing good results of the software for quantitative analysis in RT-E equipment.
The aim of this study is to establish the role of elastographic methods (ARFI and RT-E) in liver fibrosis assessment in patients with chronic viral hepatitis. This multicentric prospective trial will be approved by the ethical committee of each centre.
AIM To evaluate the role of real time elastography (ARFI and Hitachi elastography) in noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis.
MATERIAL AND METHODS
- All patients are enrolled consecutively.
- Patient data are collected (name initials, age, sex, Civil Registration Number), liver disease etiology, anthropometric data (body mass index).
- The following blood parameters are included: aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ -glutamyl transpeptidase, γ globulins, platelet count
- The following indices are calculated: AST/ALT; AST-to-platelet ratio index (APRI); AST/upper limit of normal 100/platelet count (104 /mm3 ) , and FibroIndex [1.738 0.064 x platelet count (104 /mm3 ) + 0.005 x AST (U/l) + 0.463 x γ -globulin (g/dl)]
- Transient elastography is performed using FibroScan (FibroScan, Echosens) with the patient lying in the dorsal decubitus position and with his right arm in maximum abduction. The tip of the transducer probe is placed in the median axillary line in the intercostal space corresponding to the right lobe of the liver. The pressure index on the screen indicates that the pressure applied with the probe is compatible with the measurement. Ten measurements per examination are necessary for good accuracy of the stiffness assessment, considering the final result expressed in kilopascals as the mean of the ten measurements. M and XL probes for obese patients are used.
- Hitachi Real Time Ultrasound Elastography is performed using the 5-1 MHz (EUP) convex transducer from Hitachi Preirus equipment (Hitachi Aloka Medical Tokyo, Japan). Dual imaging is set in such a manner as to be visible on the screen in a 2D image as well as in an elastographic image juxtaposed over the 2D image. The examination is underwent through two points: intercostally through the right lobe and epigastrically through left hepatic lobe. The examination is done through post-expiratory apnea without compression on the probe. The interest region (ROI) is set at 4cm², 1 cm under the liver capsule. The aria of interest is chosen so that the 2D image is as clear as possible, the large vessels avoided and the artifacts given by ribs and lungs. For each patient, 10 images are chosen with two entry points (intercostally and epigastrically). For each image the 11 parameters given by the Strain Histogram measurement software are used: mean relative strain value (MEAN); standard deviation of relative strain value (SD); percentage of low strain area (percentage of blue color area - %AREA); complexity of low strain area (calculated as perimeter 2 /area - COMP); skewness (SKEW); kurtosis (KURT); contrast (CONT); entropy (ENT); textural complexity, inverse difference moment (IDM); angular second moment (ASM); Correlation (CORR) indicates the feature value of the texture directivity.
- ARFI- Acoustic Radiation Force Impulse Technology [ACUSON S2000]. Scanning is performed with a right intercostal approach, in the right liver lobe, segment V-VIII, 1-2 cm under the liver capsule, with minimal scanning pressure applied by the operator, while the patients is asks to stop normal breathing for a moment, in order to minimize breathing motion. The operator selects the depth at which the liver elasticity is evaluated by placing a "measuring box" (10 mm long, 5 mm wide) in the desired area. The maximum depth at which ARFI measurements can be performed is 8 cm. A total of 10 valid measurements performe in every patient and a median value in m/s is calculate.
- Liver biopsy samples is takes via a right intercostal space from the right liver lobe with direct sonographic guidance. Liver fibrosis stages is evaluate semiquantitatively according to the METAVIR scoring system on an F0-F4 scale
Statistical analysis
The diagnostic performance of ARFI and RT-E for liver fibrosis will determine in terms of sensitivity, specificity, positive predictive value, negative predictive value, diagnostic accuracy and area under the receiver operating characteristic curve (AUROC).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1. the control group | – | –healthy adult volunteers |
| 2. patients with chronic hepatitis | – | –patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen) |
| 3. liver cirrhosis type B or C | – | –patients with liver cirrhosis type B or C |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The patients included in the study will be healthy voluntaries, patients with chronic hepatitis B or C and patients with liver cirrhosis. ARFI and Hitachi elastography will be performed for each patient and the results will be compared with final diagnosis. The final diagnosis (the stage) will be established based on Transient elastography and or liver biopsy.
Key inclusion criteria (8 listed)
- age over 18 years old
- Study will include three groups of patients as follows:
- There at least one reference method available for patients with chronic hepatitis (Transient elastography/ liver biopsy)
- Hepatic cirrhosis diagnosis is established using clinical and paraclinical features (ultrasonography, superior digestive endoscopy)
- A written informed consent is given to each patient
Key exclusion criteria (5 listed)
- Patients with contraindication for elastography (pregnant women or who are breastfeeding) and patients with pacemakers
- Patients with liver disease of other etiology than viral infection (autoimmune hepatitis, primary biliary hepatitis, primary sclerosing cholangitis, hemochromatosis, alfa 1-antitrypsin deficiency, or Wilson's disease)
- History of alcohol abuse (alcohol intake> 20g/day)
- Patients under treatment with hepatotoxic drugs (methotrexate, amiodarone, corticotherapy , chemotherapy, hormonotherapy)
- Patients with technically unfeasible TE: patients with ascites
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Real Time Elastography result
Time frame: up to 24 weeks
Value of real time elastography recordings for the evaluation of liver fibrosis.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2013.
- Background1. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48: 835-847. 2. V de Lédinghen, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010 Aug; 30 (7): 1043-8. 3. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012 Feb; 19 (2): 212-9. 4. Koizumi Y, Hirooka M, Kisaka Y et al. Liver fibrosis in patients with chronic hepatitis C: noninvasive diagnosis by means of real-time tissue elastography--establishment of the method for measurement. Radiology. 2011; 258: 610-617. 5. Gheonea DI, Săftoiu A, Ciurea T et al. Real-time sono-elastography in the diagnosis of diffuse liver diseases. World J Gastroenterol. 2010; 16: 1720-1726.
Related trials for Cirrhosis
Active, not recruiting
Online Prehabilitation for Patients Awaiting Liver Transplantation
Cirrhosis, Liver, Liver Transplant Surgery
RecruitingPhase 2
High Dose Albumin in Refractory Ascites
Ascites
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
RecruitingObservational study
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
End-stage Liver Disease (ESLD), Acute Liver Failure
RecruitingPhase 2
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Liver Fibrosis, Hepatic Cirrhosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adrian Saftoiu, MD, PhD principal investigator
UMF Craiova
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cirrhosis and Chronic Liver Disease, run by University of Medicine and Pharmacy Craiova at 2 sites in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Sep 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Larisa D Sandulescu, MD, PhD (+40723968354, larisasandulescu@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Real Time Elastography result (time frame: up to 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01948687, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2013.